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Abstract
Cancer and neurocognitive disorders, such as dementia and delirium, are common and serious 
diseases in the elderly that are accompanied by high degree of morbidity and mortality. 
Furthermore, evidence supports the under-diagnosis of both dementia and delirium in older adults. 
Complex questions exist regarding the interaction of dementia and delirium with cancer, beginning 
with guidelines on how best measure disease severity, the optimal screening test for either 
disorder, the appropriate level of intervention in the setting of abnormal findings, and strategies 
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aimed at preventing the development or progression of either process. Ethical concerns emerge in 
the research setting, pertaining to the detection of cognitive dysfunction in participants, validity of 
consent, disclosure of abnormal results if screening is pursued, and recommended level of 
intervention by investigators. Furthermore, understanding the ways in which comorbid cognitive 
dysfunction and cancer impact both cancer and non-cancer-related outcomes is essential in guiding 
treatment decisions. In the following article, we will discuss what is presently known of the 
interactions of pre-existing cognitive impairment and delirium with cancer. We will also discuss 
identified deficits in our knowledge base, and propose ways in which innovative research may 
address these gaps.
Keywords
Cognition; Delirium; Dementia; Mild cognitive impairment; Confusion assessment method 
(CAM); Competency; Decision-making capacity; Screening; Prevention; Treatment
1. Introduction
There is a rising incidence of both cancer and neurocognitive disorders with aging. The 
prevalence of dementia is estimated to be around 6% in persons older than 65 years and 30% 
of persons older than 90 years.1 The actual prevalence of dementia may be significantly 
different, as studies have shown that dementia is underdiagnosed in many patients. Despite 
the fact that the benefit of routine screening for cognitive impairment in older adults is 
unclear,2 older patients with cancer represent a vulnerable subset, where assessment of 
decisional capacity is essential. Although patients with dementia may be able to relay 
preferences in regard to daily activities and care, they may lack the ability to make more 
complex decisions such as those involving cancer treatment. The implications of even mild 
cognitive impairment are significant, given that these patients may be at high risk for 
developing dementia.3 In the setting of cancer treatment decisions hold significant 
consequences, patients must be able to demonstrate a high degree of understanding and 
ability to process information in order to proceed with active treatment.
Delirium is also a common, often under-recognized 4 neuropsychiatric problem associated 
with substantial morbidity, mortality, and a high potential impact on decision-making ability. 
The vast majority of studies on the prevalence and impact of delirium have focused on 
hospitalized general medicine or postoperative patients, as opposed to older adults with 
cancer. The lack of awareness of delirium incidence and prevalence is especially problematic 
in the outpatient setting where much of cancer care is delivered.5
Both dementia and delirium can contribute significantly to morbidity and mortality in the 
elderly and are important factors for patients in a number of treatment settings. The 
coexistence of cancer and dementia or delirium has dramatic implications on treatment 
decisions and outcomes. The objective of this article is to identify and address gaps 
pertaining to the diagnosis, screening, and treatment of cognitive impairment and delirium in 
the older adult cancer patient population. The case study in Table 1 illustrates how these 
conditions may present, and the issues that arise. This manuscript will address gaps in 
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knowledge and how dedicated research in this area can help close these gaps. In addition, 
issues related to protection of patients with cognitive impairment in research are discussed.
2. GAP 1: The optimal way of identifying and measuring pre-existing 
cognitive impairment in older adults with cancer is not known
Dementia is often misdiagnosed. One study found that the diagnosis of dementia was missed 
in 21% of patients on a general medical ward, and 20% of patients without dementia were 
misdiagnosed with the condition.6 The presence of several diagnostic classification schemes 
may lead to different diagnostic conclusions. A study of 1879 people aged 65 years and 
older enrolled in the Canadian Study of Health and Aging revealed that the prevalence of 
dementia can differ by a factor of 10 depending on which diagnostic criteria are used, which 
has important implications for treatment and research.7 Although several definitions for 
dementia exist, the definition set by the Diagnostic and Statistical Manual (DSM) provides a 
reasonable framework readily applicable to clinical practice.8 According to the DSM-5, a 
diagnosis of dementia requires significant cognitive impairment in at least one of 6 domains 
apparent from history and clinical assessment (learning and memory, language, executive 
function, complex attention, perceptual-motor function, and social cognition). The identified 
deficit(s) must represent a decline from a previous level of function, and interfere with 
independence in everyday social and occupational function. The major dementia syndromes 
include Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, vascular 
dementia, and Parkinson disease with dementia. Less common disorders include progressive 
supranuclear palsy and dementia related to Huntington's disease. Alzheimer's dementia is the 
most common subtype of dementia in the general elderly population. It represents 60–80% 
of dementia cases, with a prevalence of 5–7% in most counties.9 Vascular dementia 
represents the second most common form of dementia, comprising approximately 10–20% 
of cases in North American and Europe, with an estimated prevalence of 1.2–4.2% in 
patients 65 and older.10,11 In patients with cancer, the precise incidence of various subtypes 
of dementia is unknown. However, using SEER Medicare data, the incidence of memory 
loss (defined as impairment causing interference with daily activities) and dementia has been 
found to be around 12%.12 Each subtype is clinically distinguishable by history, physical 
signs/symptoms, and imaging. Disturbances are insidious and progressive in the case of 
neurodegenerative dementias such as Alzheimer's, as revealed through serial cognitive 
function exams examinations, and cannot be accounted for by another mental disorder (such 
as depression, schizophrenia, or delirium).13 Given the prevalence of depression, it is 
particularly important for practitioners to concurrently screen for depression at the time of 
initial evaluation.
Garnering increasing attention is the entity of mild cognitive impairment (MCI). Findings of 
longitudinal population studies, applying varied definitions of MCI, estimate that the 
prevalence of MCI in the general elderly population is anywhere from 3% to 19%, and the 
risk of MCI progressing to dementia in a 2-year time-frame is 11–33%.14,15 MCI is 
generally recognized as cognitive decline that is greater than expected for a patient's age but 
does not impact function in daily life.15,16 Table 2 highlights several different definitions 
applied to cognitive impairment syndromes.17
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General consensus-based guidelines recommend that providers use cognitive assessment 
tools when evaluating older patients with cancer to screen for baseline impairments, to 
evaluate cognitive capacity, with comprehensive work-up pursued in those with abnormal 
scores.18 Assessment of cognitive function is included as a domain in the comprehensive 
geriatric assessment (CGA). Several tools are available (summarized in Loh et al. in this 
supplement), although not all have been fully tested or compared for predictive validity or 
impact on outcomes.19 Several studies have shown that the incidence of cognitive 
impairment (CI) as detected by screening undertaken during the CGA ranges between 24% 
and 38%.20–23 Thein and colleagues demonstrated in a retrospective chart review of 191 
patients that the overall prevalence of CI, including dementia, using the Mini-cog tool, was 
35%.24 In another prospective study in which 50 patients were administered a CGA at 
baseline, 27% were found to have cognitive impairment.22,25 However, evidence is also 
available supporting a lower rate of cognitive impairment in the older patient with cancer 
considered functionally normal by the Karnofsky Performance Status, with one study 
showing that the incidence of cognitive dysfunction as rated by the Blessed Orientation 
Memory Concentration Test (BOMC) was less than 10%.26 Comprehensive 
neuropsychological testing is not necessary for all patients but may be useful for diagnosis 
and evaluation of decision-making capacity in patients with substantial cognitive 
impairment, including dementia, those with significant brain damage (stroke, head injury), 
or other neurological disease.
More observation and registry studies are needed to gain better understanding of the 
prevalence and incidence of dementia and cognitive impairment in patients with cancer. 
Using SEER Medicare data, Mohile and colleagues were able to demonstrate a comparable 
presence of memory loss and dementia in elderly patients with a history of cancer and those 
without a history, of 11.6% and 10.4%, respectively (p-value = 0.1773).12 Further studies are 
needed that apply a designated set of validated criteria to newly diagnosed elderly patients 
with cancer, placing focus on the full spectrum of cognitive impairment, not restricted to 
dementia alone. In order to capture the diagnosis to begin with, studies comparing the 
positive and negative predictive values of various screening methods in this population are 
also imperative.
3. GAP 2: The impact of underlying cognitive impairment on cancer care is 
unclear
Another deficit pertaining to treatment of cancer in patients with pre-existing cognitive 
impairment is the impact on subsequent treatment and disease-related clinical outcomes. 
Few published studies have evaluated outcomes in patients with cognitive dysfunction who 
receive systemic therapy. Patients with cognitive impairment may have greater difficulty 
understanding the nature of the diagnosed cancer and its prognosis, in addition to the risks 
and benefits associated with treatment. Furthermore, such deficiencies may cause difficulty 
processing instructions on treatment regimens and reporting side effects that could impact 
their treatment and disease-related outcomes. They may also have a difficult time expressing 
their cancer-related syndrome burden, which impacts delivery of appropriate palliative 
interventions such as analgesia and subsequently diminishes quality of life. In most cases, 
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patients with mild cognitive impairment/dementia have intact decision-making capacity and 
require clear communication from a medical provider regarding various options and 
provisional support from their families and/or caregivers. Prior studies have shown that 
patients with comorbid physical and mental illness are at greater risk for morbidity and 
mortality, which would apply to the cancer patient population as well.27 A more recent study 
found that 61% of patients with dementia had significant physical illness.28 Furthermore, 
studies have shown that patients with dementia have a shorter life expectancy than is often 
times estimated by both clinicians and family members, which should be taken into account 
during clinical decision making for cancer treatment.29 However, further research is needed 
to determine whether patients with mild cognitive impairment are at heightened risk for 
adverse effects from cancer treatment, and how pre-existing impairment impacts decision-
making.
Several studies report an association between a diagnosis of pre-existing dementia with 
diagnosis of cancer at a later stage. One study of 17,500 older patients with colon cancer 
found that a pre-existing diagnosis of dementia was associated with lower odds of 
undergoing diagnostic tissue biopsy, higher odds of having unstaged cancer, and subsequent 
lower likelihood of receiving curative intent therapies.30 A second study of 50,460 older 
patients with breast cancer revealed that dementia was independently associated with a 
diagnosis of later-stage breast cancer.31 Raji and colleagues conducted a retrospective cohort 
study of patients with breast, colon, and prostate cancer that also showed an association 
between pre-existing dementia and diagnosis of disease at later stages. Furthermore, they 
also showed that the effect of cancer stage at diagnosis on mortality was significantly higher 
in older patients with pre-existing dementia.32
Further studies are needed to understand how the presence of pre-existing cognitive 
impairment or dementia affects chemotherapy-related adverse effects, hospitalization, post-
treatment surveillance, cancer recurrence, and patient-reported outcome measures. Studies 
accomplishing this could be of various types, including observational, case–control, and 
cohort studies and cross-sectional studies. Ultimately, such studies would further allow us to 
best determine the degree to which a diagnosis of cognitive impairment or dementia may 
impact cancer treatment.
4. GAP 3: There are no standard procedures to manage abnormal cognitive 
screening test results that are found during research studies
Cognitive impairment is underdiagnosed in older adults with cancer. However, as cognitive 
screening is increasingly incorporated into clinical care and research of older adults with 
cancer, clinicians and investigators must consider the implications of an abnormal cognitive 
screen on treatment decisions. If cognitive screening is performed, particularly within the 
context of clinical research, there are ethical issues that may arise around disclosure, 
responsibilities of the research team and health care providers, and whether the research and 
treatment consent can be considered valid. No current framework exists to address these 
issues leading to a lack of uniformity in dealing with these issues across different 
institutions.
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There is currently no consensus as to whether researchers are obligated to or should inform 
patients and/or their primary care professional about results of cognitive testing done within 
the context of clinical research. Some institutions mandate disclosure of incidentally found 
cognitive findings, while others do not. Generally, researchers have an obligation to disclose 
incidental findings either to a clinician or the patients themselves, which may have 
“clinically important implications on patient health”.33 Differences in policies may stem 
from the uncertain implications of an abnormal cognitive screen, as a positive cognitive 
screen does not equate to a diagnosis of dementia. Depending on the cognitive test used, the 
specificity for dementia can range from 50% to 96%.34–36 With further testing, patients may 
be found to have normal cognition (false positive), MCI, or dementia.2 In addition, other 
conditions, such as depression, delirium, and medications, can result in a positive cognitive 
screen and must be ruled out.
The uncertain benefit of earlier MCI diagnosis likely also factors into the complex decision 
to disclose or not disclose positive results. MCI, by definition, has no impact on a patient's 
ability to function independently. Although patients with MCI are at higher risk of 
developing dementia, the likelihood of this ranges considerably.3,37–39 Furthermore, there 
are currently no effective pharmacological interventions for MCI,36,37 although optimization 
of vascular risk factors, cognitive stimulation, and engagement of community resources may 
be beneficial.37,40 Even for patients diagnosed with dementia, it is unclear whether 
pharmacologic intervention translates into a clinically significant benefit.36 While the 
psychological impact related to a false-positive cognitive screening test is unknown,36 
several studies suggest that patients fear a diagnosis of dementia due to the potential stigma 
associated with this diagnosis,40–43 as well as the possible impact it may have on their 
ability to drive and live independently.44 It should be noted that some patients may not wish 
to know if they have abnormal cognitive screening and that 48–67% of patients who have a 
positive cognitive screen refuse to undergo further testing.41,45,46 Thus, given that abnormal 
cognitive screening does not imply a diagnosis of dementia and that earlier diagnosis of 
cognitive impairment may not translate into better outcomes, it is unclear whether or not 
these results need to be conveyed to patients or their primary care physician.
The decision to disclose findings to a patient is further complicated in situations in which the 
researcher has no therapeutic relationship to the patient, such as in testing of volunteers used 
for controls. In these cases, it unclear what responsibility the researcher may have to the 
subject, and whether results should be relayed directly to the patient from the researcher, or 
if such information would best come from a physician with whom the patient has an 
established therapeutic relationship with, such as their primary care physician, who can 
explain the implications of the test result and arrange for further testing if necessary.
Finally, if patients are found to have cognitive impairments, this may have significant 
implications on the treatment plan and the validity of the patient's consent. The presence of 
cognitive impairment, particularly dementia, can influence both the potential benefits of 
chemotherapy, particularly in the adjuvant setting, as well as its potential harms. 
Chemotherapy can worsen cognition in some patients, which would be undesirable. Patients 
with cognitive impairment may have more difficulty understanding the risks and benefits of 
treatment and adhering to complex cancer treatment regimens. This is particularly relevant 
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in the current era where obtaining written informed consent prior to undertaking treatment is 
becoming increasingly common in clinical practice. In clinical research, rigorous procedures 
exist to ensure patients are well informed about the risks and benefits of participation in 
research, for the purpose of protecting patients. Yet these consent forms and procedures are 
often complex and may be difficult for patients with cognitive impairments to understand.
However, a diagnosis of cognitive impairment or dementia does not necessarily mean that 
the patient is incapable of making decisions and consenting.47,48 In fact, most patients with 
MCI and many patients with early dementia are still able to understand the risks and benefits 
of treatment and of being involved in research, although this ability may fluctuate and vary 
depending on the task and complexity of the decision.48,49 It is important that researchers do 
not automatically exclude patients with any cognitive impairment from clinical research, but 
that every effort be made to ensure that patients enrolled in studies do have the capacity to 
consent. Broadly, patients are deemed to have the capacity to make a decision if they 
demonstrate understanding of the situation, appreciate how the decision affects them 
personally, and are able to express a choice and the reasoning behind the choice.50 The 
MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR) is a 
commonly used instrument to determine decision-making capacity.51 In patients who are not 
capable of providing consent for research purposes, the American Geriatric Society suggests 
that a surrogate decision maker should be able to consent for research on the patient's 
behalf.48 However, patient assent (agreement) or dissent for a particular decision should still 
be sought. In those studies that pose a greater than minimal risk and which do not have a 
reasonable likelihood of direct benefit to the patient, the American Geriatric Society 
suggests that these studies should not be offered patients who do not have the capacity to 
consent.48
A common strategy is needed to guide researchers on how best to handle abnormal cognitive 
screening findings. It is important that all stakeholders, including patients as well as 
regulatory bodies, be involved in providing guidance on the development of standardized 
protocols to address this important issue. As part of this process, it will be important to 
determine the threshold of cognitive impairment that is felt to have clinically significant 
implications on patient health, and at which researchers are obligated to inform patients, 
caregivers, and patients’ physicians. In the absence of existing guidelines/framework, we 
propose that patients should be asked prior to testing whether they wish to know the results 
of their cognitive screen if positive and that patients and investigators should discuss the 
potential implications of such a result prior to consenting for testing.
5. Gap 4: Patients with cancer are not routinely screened for delirium or 
delirium risk
Delirium is a condition that can lead to serious complications including increased morbidity 
and mortality,52,53 functional54 and cognitive decline,55,56 and caregiver burden and 
distress.57–59 It is characterized by an acute onset of disturbances in attention, awareness, 
and cognition that are not caused by a pre-existing cognitive disorder.60 Making the 
diagnosis of delirium is complicated by similarity in presentation to other disease processes. 
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Similar to delirium, Lewy Body Dementia is characterized by fluctuating effects on mental 
functions, particularly in alertness and attention.61 Sundown syndrome is another distinct 
clinical entity formally recognized in the DSM-V that can be difficult to distinguish from 
delirium. It occurs more frequently in the cognitively impaired or institutionalized patient 
population but is characterized by behavioral disturbances and mood alteration that occurs 
specifically in the later afternoon or evening.62 It is important to discern the prevalence and 
impact of delirium in older patients with cancer since the risk of delirium is associated with 
both increased age63 and malignancy.64 Estimates of the prevalence of delirium in patients 
with cancer range widely from 10% to 50% among inpatients undergoing cancer 
surgery65–69 and 20% to 90% among patients with advanced cancer receiving palliative 
care.70–73 Without routine evaluation for delirium in outpatient cancer clinics, it is difficult 
to estimate the true prevalence of delirium among patients with cancer.
Screening for delirium in patients with cancer may be challenging since cancer itself may 
cause similar symptoms such as lethargy and decreased awareness, two potential signs of 
hypoactive delirium. Hypoactive delirium is the most common subtype and is more likely to 
be underdiagnosed compared with hyperactive or mixed delirium.4,74 Delirium can be 
clinically assessed using a variety of screening instruments, with the Confusion Assessment 
Method75 being the most well-validated and widely used approach. The diagnosis is 
established according to DSM-5 60 or ICD-10 criteria.76 Delirium severity is commonly 
measured using the Memorial Delirium Assessment Scale (MDAS),77 Delirium Rating 
Scale-Revised 98 (DRS-R-98)78 or CAM-S, which is the only delirium severity tool that has 
been validated against clinical outcomes.75 More research is needed to understand how to 
best apply delirium screening tools to community-dwelling patients with cancer. Delirium is 
also difficult to retrospectively identify in clinical research utilizing secondary data analysis. 
A validated chart-based delirium instrument demonstrated a sensitivity of 74% and 
specificity of 83%.79 This may limit what can be learned about delirium from large 
population-based cancer databases, where sensitivity analyses would be important to 
determine the potential impact of underrecognition or misclassification.
In addition to provider assessments of delirium in patients with cancer, family caregiver 
perspectives outside the formal clinic environment may provide unique information on 
delirium symptoms in between visits. In one of the few studies of delirium in cancer 
outpatients, caregivers of patients with head and neck cancer retrospectively reported higher 
rates of delirium compared with provider clinical assessments.5 To incorporate the family 
perspective, the developers of the CAM created a second delirium screening instrument to be 
administered by caregivers, the Family-CAM (FAM-CAM).80 The FAM-CAM has a 
sensitivity of 86% and a specificity of 98% compared with the CAM and is designed to be 
used in conjunction with or confirmed by providers. The implementation of the FAM-CAM 
and other caregiver-based delirium assessment tools to identify delirium in community-
dwelling patients with cancer needs to be further investigated.
To fill this gap, researchers need to first determine the true incidence of delirium among 
patients with cancer in order to identify the extent of the problem. Researchers also need to 
investigate the optimal screening tool to use in this specific patient population. The CAM 
has been validated in the inpatient hospital and emergency room settings but additional 
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studies of the CAM in outpatient cancer treatment centers are needed. Targeted screening 
and monitoring of high-risk patients for delirium would likely be the optimal approach in 
outpatient cancer treatment center. The recommended frequency of repeated delirium 
assessments is also unknown. Once screening for delirium has been performed, oncologists 
need education and training on how to respond to a positive result to confirm the diagnosis 
of delirium, to minimize its duration and complications, and to develop a plan to prevent its 
recurrence. Oncology nurses may be well poised to assist with this effort since nurses have 
been instrumental in delirium screening and prevention in hospitalized patients through 
multidisciplinary programs such as the Hospital Elder Life Program.81 To improve 
identification of delirium in large cohorts, clinical trials of older patients with cancer should 
also consider adding an assessment of delirium as a patient-centered adverse event.
6. Gap 5: Too few studies focus on the prevention and treatment of delirium 
in older adults with cancer
Patients with cancer are at increased risk for delirium compared with those without cancer 
due to potential direct effects of cancer on the central nervous system from brain metastases 
or paraneoplastic syndromes, uncontrolled symptoms such as pain, nausea, and constipation, 
and toxicity from chemotherapy82 and supportive medication including opiates, 
benzodiazepines, anti-emetics, diphenhydramine, and corticosteroids. These supportive 
medications commonly used in cancer care may be of concern in older patients with cancer, 
who are at higher risk for delirium. Cancer and its treatment may also augment traditional 
delirium risk factors including multimorbidity, polypharmacy, infections, metabolic 
derangements, insomnia, and malnutrition. A recent study of geriatric assessment for older 
patients prior to cancer surgery found that the Charlson Comorbidity Index, the dependence 
on IADLs, and a history of falls predicted postoperative delirium.83 Preoperative cognition 
and severity of the surgical procedure have also been shown to be independent risk factors 
for postoperative delirium after cancer surgery.84
Delirium has been shown to be preventable in 30–40% of cases.81,85 Several successful 
strategies for delirium prevention have been developed including the multicomponent non-
pharmacologic Hospital Elder Life Program,81,86 proactive geriatric consultation,87 and 
exercise and rehabilitation interventions.88,89 A recent meta-analysis concluded that 
multicomponent non-pharmacologic delirium interventions in non-cancer-specific 
populations were effective.90
Despite the advances in delirium prevention in non-cancer settings, studies of delirium 
prevention in patients with cancer have been limited, and the few interventions studied have 
not demonstrated efficacy (Table 3). Gagnon and colleagues tested a multicomponent 
delirium prevention intervention for inpatient hospice patients with terminal cancer.91 The 
intervention consisted of a delirium risk assessment, nursing reorientation, and family 
education about delirium, but it was not effective at decreasing delirium incidence or 
severity. Hempenius et al. conducted a randomized controlled trial of a geriatric liaison 
intervention to prevent postoperative delirium after elective surgery for a solid tumor.92 
Again, there was no difference in the incidence of delirium between the intervention and 
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usual care groups. Concerns have been raised about the potency of the interventions in both 
of these studies.
To fill this knowledge gap, studies on delirium prevention in older patients with cancer are 
key since the treatment of delirium after its onset is challenging. The American Geriatrics 
Society postoperative delirium guideline also emphasizes the importance of delirium 
prevention.93 Interventions for randomized clinical trials need to be of adequate potency and 
the optimal delirium endpoint should be selected carefully to accurately measure hypoactive, 
hyperactive, and mixed delirium without overweighting agitation. Discussion with 
stakeholders and pilot studies conducted with multidisciplinary input should be undertaken 
prior to randomized studies. Pragmatic trials of proven interventions (Table 3) applied to 
patients with cancer should be considered because the results can potentially be 
disseminated in real-world oncology settings. However, this trial design may require a large 
sample size, produce less definitive results, and be significantly influenced by confounding 
factors. Quality improvement trials studying the incidence of delirium before and after an 
intervention may be useful for interventions where effectiveness and cost-effectiveness have 
been established. This type of trial design may produce convincing local evidence but may 
be susceptible to temporal trends and may not be generalizable to other settings. 
Furthermore, studies on how to optimize oncologic supportive medications in older adults to 
minimize delirium are needed to develop more specific evidence-based guidelines.
Once delirium has occurred, management commonly begins with an evaluation of potential 
precipitating and aggravating factors and correction of any modifiable risk factors to 
minimize complications and the duration of symptoms. Pharmacologic treatment for 
hyperactive delirium such as haloperidol or atypical antipsychotics may be necessary if non-
pharmacologic strategies for agitation are not sufficient. Older patients are more susceptible 
to side effects from antipsychotics and patients with cancer may have numerous 
comorbidities and potential drug interactions to consider as well. As with delirium screening 
and prevention, studies of pharmacologic treatments for delirium specifically in patients 
with cancer are few and sample sizes have been small.94 To better understand how to treat 
delirium in older patients with cancer, qualitative studies to address barriers and challenges 
to implementing behavioral and pharmacologic treatments for delirium in oncology are 
needed. The development of effective education and training materials on delirium treatment 
for oncologists and studies of the feasibility of implementing proven treatment approaches in 
an oncology setting will help advance our ability to decrease the burden of delirium on 
patients with cancer.
7. Conclusion
With the growing aging population, the number of older adults with both cancer and 
cognitive impairment is predicted to increase. The major challenge faced by health care 
providers will be the optimal way to both address and manage these co-existing conditions. 
Decision making and interventions will ultimately be best facilitated by early identification 
of cognitive impairment. Finally, further research is needed to determine how best to identify 
and monitor these conditions and understand the ways in which cancer-related and quality-
of-life outcomes are impacted. Included in Table 4 is a summary of key research priorities 
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that will enable health care providers to better understand the implications of comorbid 
cognitive dysfunction and cancer in elderly patients.
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Table 1
Case study.
Case Mr. HF is a 70-year-old Caucasian man with a 50-pack-year smoking history and past medical history of hypertension and 
hyperlipidemia. He was diagnosed with metastatic lung cancer to the bone after presenting with a progressive mild cough over the 
course of 2 months. Imaging revealed a large right-middle-lobe lung mass measuring 4 cm, with associated mediastinal 
lymphadenopathy. Bronchoscopy was performed soon thereafter, confirming the diagnosis of non-small cell adenocarcinoma, 
EGFR/ALK non-mutated. PET-CT demonstrated multiple bone lesions consistent with metastatic involvement.
On initial evaluation by his medical oncologist to consider treatment options, he reported that apart from mild cough, he felt very 
well. His medical comorbidities of hypertension and hyperlipidemia were well managed for a number of years with medications. 
He was formerly employed as an attorney and had been retired for the past 15 years. He was accompanied to his appointment by 
his daughter but stated that he lived alone since losing his wife to a sudden heart attack 1 year prior. He noted that he was doing 
well in the adjustment period of living alone, taking care of his house, grocery shopping, preparing his own meals, and spending 
much of his free time with his young grandchildren who lived nearby and also volunteering his time at a free legal clinic in his 
community. He denied any feeling of sadness or anxiety. Upon further probing, his daughter did express that her father had 
periodic issues with his memory at time, such as social plans they made together. Lately, he also had been requesting her oversight 
in paying bills and managing his finances. After further discussion, the plan was to start him on first-line systemic therapy with 
doublet therapy that included carboplatin/pemetrexed.
Two weeks after receiving his first cycle of treatment, he was brought to the emergency room (ER) by his daughter for evaluation 
of new onset confusion and difficulty performing even simple activities of daily living (bathing, feeding himself, etc). He had 
noted disturbances in his sleep pattern 1 week prior and had been taking lorazepam to help him fall asleep. His daughter was 
uncertain but believed he has been taking lorazepam regularly. In the ER, he was alert and oriented only to his name and was 
unsure of time or place. He was slightly agitated and combative when physical exam was attempted. Vital signs were within 
normal limits. MRI of the brain was performed revealing no abnormalities. Labs (including complete metabolic panel, B12, folic 
acid, TSH) revealed no abnormalities.
Questions What other assessments could have taken place at his initial evaluation, prior to starting treatment (GAP 1)? What does an 
abnormal screening test of cognitive impairment mean in this patient population and what are the implications in treatment 
decision making (GAP 2)?
GAP 1: The optimal way of identifying and measuring pre-existing cognitive impairment in older adults with cancer is not known.
GAP 3: There are no standard procedures to manage abnormal cognitive screening test results that are found during research 
studies.
What is known about the patterns of cancer care for patients with cognitive impairment? (GAP 2)
GAP 2: The impact of underlying cognitive impairment on cancer care is unclear.
Are there any risk factors for the development of delirium and should routine screening be done (GAP 4)? Are there ways to treat 
or prevent delirium in older adults with cancer (GAP5)?
GAP 4: Patients with cancer are not routinely screened for delirium.
GAP 5:There are too few studies focus on the prevention and treatment of delirium in older adults with cancer.
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Table 2
Definitions of cognitive impairment syndromes.
Term Diagnostic criteria Source
Age-associated memory impairment Subjective and objective memory impairment compared with that of a young adult Crook et al. 95
Benign senescent forgetfulness Complaints of memory Kral et al.96
Age-related cognitive decline Objective decline in cognitive function not otherwise specified DSM 513,60,97
Aging-associated cognitive decline Age-adjusted impairment in any cognitive task Levy et al.98
Mild neurocognitive decline Impairments in memory, learning, perceptual-motor, linguistic, or executive 
functioning
DSM V13,97
Mild cognitive decline Impairment in cognitive tests of learning, concentration or memory secondary to a 
defined illness
ICD-1076
Mild cognitive impairment Subjective and objective memory impairment in the absence of dementia adjusted 
for age and education
Peterson et al.99
Cognitive impairment—no dementia Impairments in memory, learning, perceptual-motor, linguistic, or executive 
function in the absence of clinically diagnosed dementia
Graham et al. 100
Delirium Acute and fluctuating impairments inattention and global cognitive functioning DSM 560
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Table 3
Delirium risk factor identification and prevention studies in (A) cancer-specific and (B) non-cancer-specific 
populations.
Study Study population Intervention Delirium measure Outcome Comments
(A) Cancer-specific studies
Delirium risk 
factor 
identification: 
Korc-Grodzicki 
et al.83 
(retrospective 
single-center 
cohort study)
416 patients aged 
≥75 years 
undergoing major 
surgery for a solid 
tumor in the US. 
Median age, 80 
years (range 75–98 
years).
Preoperative geriatric assessment Confusion 
Assessment 
Method (CAM)75
Postoperative 
delirium 
identified in 
19% of patients. 
Delirium 
associated with 
the Charlson 
Comorbidity 
Index (adjusted 
OR = 1.82, 95% 
CI = 1.05–3.15) 
and IADL 
dependence 
(adjusted OR = 
2.07, 95% CI = 
1.18–3.64).
Geriatric 
assessment may 
be a useful tool to 
identify patients 
with cancer at 
high risk for 
postoperative 
delirium for 
future delirium 
prevention trials.
Delirium risk 
factor 
identification: 
Hempenius et 
al. 84 
(retrospective 
multicenter 
observational 
study)
251 patients aged 
>65 years 
undergoing elective 
surgery for a solid 
tumor in the 
Netherlands. Mean 
age (SD): 74.2 (6.4) 
years.
Preoperative Groningen Frailty 
Indicator (GFI)101
Inouye chart-based 
delirium 
instrument79
Postoperative 
delirium 
identified in 
18.3% of 
patients. 
Delirium 
associated with 
preoperative 
GFI cognitive 
functioning 
(adjusted OR = 
23.36, 95% CI = 
5.33–102.36) 
and severity of 
surgery 
(intermediate 
surgery OR = 
15.44, 95% CI = 
1.70–140.18; 
major surgery 
adjusted OR = 
45.01, 95% CI = 
5.22–387.87).
Preoperative 
cognition and 
severity of 
surgery are 
important 
delirium risk 
factors and may 
be useful to 
identify high-risk 
patients for future 
trials.
Delirium 
prevention: 
Gagnon et al. 91 
(nonrandomized 
multicenter trial)
1,516 patients with 
cancer residing in 7 
Canadian palliative 
care units. Mean age 
(SD): 67.6 (13) 
years intervention 
group vs 69.1 (12.9) 
years usual care 
group.
Multicomponent preventive 
intervention (nurse identification 
of delirium risk factors, patient 
and family delirium symptom 
education, routine patient 
reorientation) vs usual care
Confusion Rating 
Scale (CRS) 102
Incidence of 
delirium was 
49.1% in the 
intervention arm 
vs 43.9% in the 
usual care arm 
(p = 0.045). 
After 
controlling for 
confounders, 
there was no 
difference in 
incident 
delirium (p = 
0.66).
Delirium 
prevention 
intervention may 
have lacked 
potency.
Delirium 
prevention: 
Hempenius et 
al. 92 
(multicenter 
randomized 
controlled trial)
251 patients age >65 
years undergoing 
elective surgery for 
solid tumor in the 
Netherlands. Mean 
age (SD): 77.45 
(6.72) years 
intervention group 
vs 77.63 (7.69) 
Geriatric liaison intervention 
(preoperative geriatric 
consultation with individualized 
treatment plan, daily geriatric 
nurse visits during admission) vs 
usual care
Delirium 
Observation Scale 
(DOS) 103
Postoperative 
delirium 
identified in 
11.9% of 
patients. No 
difference in the 
incidence of 
delirium in the 
intervention 
Delirium 
prevention 
intervention may 
have lacked 
potency.
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Study Study population Intervention Delirium measure Outcome Comments
years usual care 
group
group (9.4%) vs 
the usual care 
group (14.3%), 
OR = 0.63, 95% 
CI = 0.29–1.35.
(B) Non-cancer-specific studies
Delirium 
prevention: 
Inouye et al. 81 
(single-center 
matched 
controlled trial)
852 hospitalized 
general medicine 
patients in the US. 
Mean age (SD): 
79.6 (6.1) years 
intervention group 
vs 79.8 (6.2) years 
usual care group; 
3% with cancer.
Multicomponent preventive 
intervention—Hospital Elder Life 
Program (interdisciplinary 
standardized management of six 
delirium risk factors: cognitive 
impairment, sleep deprivation, 
immobility, visual impairment, 
hearing impairment, dehydration) 
vs usual care
CAM 9.9% of the 
intervention 
group developed 
delirium vs 
15.0% of the 
usual care group 
(matched OR = 
0.60, 95% CI = 
0.39–0.92). 
Once delirium 
occurred, there 
was no 
difference in the 
severity of 
delirium or 
recurrence.
Studies that adapt 
this efficacious 
multicomponent 
intervention to 
cancer 
populations are 
needed.
Delirium 
prevention: 
Marcantonio et 
al. 87 (single-
center 
randomized trial)
126 patients aged 
≥65 years admitted 
emergently for 
surgical repair of hip 
fracture in the US. 
Mean age (SD): 79 
(8) years.
Proactive geriatrics consultation 
(daily visits with targeted 
recommendations per structured 
protocol) vs usual care
CAM Postoperative 
delirium 
occurred in 32% 
of intervention 
patients vs 50% 
of usual care 
patients (RR = 
0.64, 95% CI = 
0.37–0.98).
The efficacy of 
proactive 
geriatrics 
consultation 
should also be 
studied in 
hospitalized and 
community-
dwelling patients 
with cancer.
Delirium 
prevention: 
Caplan et al. 88 
(randomized 
controlled trial)
104 Australian 
hospitalized patients 
referred for geriatric 
rehabilitation 
randomized to home 
rehab (early 
discharge) vs 
hospital rehab. 
Mean age (SD): 
83.9 (7.8) years 
home rehab vs 84.0 
(7.0) years hospital 
rehab.
Home rehab (multidisciplinary 
outreach team including nurses, 
physical therapists, occupational 
therapists, and providers plus an 
acute admission substitution 
service) vs hospital rehab 
(geriatric rehab ward care)
CAM Home rehab 
group had lower 
odds of 
developing 
delirium (OR = 
0.17, 95% CI = 
0.03–0.65) and 
shorter duration 
of rehab (15.97 
vs 23.09 days, p 
= 0.0164).
The home-based 
rehab 
intervention is a 
valuable example 
of decreasing 
delirium risk in 
the outpatient 
setting. Potential 
applications of 
this intervention 
to outpatient 
cancer care 
should be 
studied.
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Table 4
Summary of key research priorities to better understand cognition in older patients with cancer.
1. Define the optimal way to identify and measure pre-existing cognitive impairment in older patients with cancer.
    a. Cognitive assessment tools should be utilized both in clinical practice and in research studies to screen for baseline impairments and assess 
cognitive capacity. Abnormal scores warrant a comprehensive evaluation.
    b. More observational and registry studies are needed to better estimate the prevalence and incidence of dementia and cognitive impairment 
in patients with cancer.
2. Conduct further studies on the impact of pre-existing cognitive impairment or dementia on cancer treatment and toxicity, hospitalization, 
post-treatment surveillance, and cancer recurrence.
3. Develop a standardized framework on how to manage abnormal cognitive screening results performed for research purposes.
    a. Standardized framework should include guidelines on obtaining patient preferences for disclosure of abnormal test results at study 
enrollment, threshold of clinically significant cognitive impairment, when to disclose abnormal results and to whom.
    a. Improve detection of delirium in older patients with cancer with improved screening and monitoring of high-risk patients in the outpatient 
setting, and improved screening and monitoring of all older patients in inpatient settings. Delirium screening tools need to be studied in 
community-dwelling patients with cancer to better estimate the incidence of delirium during cancer treatment.
    b. Family caregiver reported outcomes may provide unique information on delirium symptoms in between clinical assessments.
    c. Improved methods to assess delirium risk in patients with cancer.
4. Conduct more studies focused on the prevention and treatment of delirium in older patients with cancer.
    a. Delirium interventions for randomized controlled trials need to be of adequate potency and require stakeholder and multidisciplinary input.
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